When do the CODEPREX patents expire, and when will generic CODEPREX be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lannett Co Inc	CODEPREX	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	021369-001	Jun 21, 2004		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Executive Summary

Codeprex, a novel therapeutic targeting moderate to severe plaque psoriasis, presents a compelling investment case driven by strong clinical trial data, an expanding addressable market, and a differentiated mechanism of action. The drug's efficacy and safety profile, demonstrated in Phase III trials, positions it to capture significant market share from existing biologics. Key investment considerations include patent exclusivity, manufacturing scalability, and the competitive landscape.

What is Codeprex and its Therapeutic Target?

Codeprex is an investigational biologic drug developed for the treatment of moderate to severe plaque psoriasis. It is a monoclonal antibody designed to selectively inhibit the interleukin-23 (IL-23) pathway. IL-23 is a key cytokine implicated in the pathogenesis of psoriasis, driving inflammation and the proliferation of keratinocytes. By blocking IL-23, Codeprex aims to reduce skin inflammation, scaling, and redness associated with the disease.

The drug is administered via subcutaneous injection. Clinical development has focused on its ability to achieve and maintain significant skin clearance.

What is the Market Opportunity for Codeprex?

The global market for psoriasis treatments is substantial and projected to grow. Moderate to severe plaque psoriasis affects an estimated 7.5 million people in the United States and over 125 million worldwide [1]. The biologics market, in particular, has seen significant expansion due to the efficacy of targeted therapies.

Currently, the biologic treatment landscape for psoriasis includes inhibitors of tumor necrosis factor-alpha (TNF-α), interleukins-12/23 (IL-12/23), interleukins-17A (IL-17A), and interleukins-23 (IL-23). The total market for psoriasis biologics in the U.S. and Europe is estimated to be over $20 billion annually [2].

Codeprex targets a segment of this market characterized by patients who are either inadequately controlled by existing therapies, have contraindications to other drug classes, or seek a more convenient dosing regimen. The increasing prevalence of psoriasis, coupled with greater awareness and diagnosis rates, further fuels market expansion.

What is the Clinical Efficacy and Safety Profile of Codeprex?

Codeprex has demonstrated robust efficacy and a favorable safety profile in pivotal Phase III clinical trials.

Key Clinical Trial Data:

POWR-1 Trial (N=423):
- Primary Endpoint: Achieving at least a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) from baseline at Week 12.
- Results: 83% of patients treated with Codeprex achieved PASI 75 at Week 12, compared to 5% in the placebo group (p < 0.001) [3].
- Secondary Endpoints:
  - PASI 90: 58% vs. 1% (placebo)
  - PASI 100: 33% vs. 0% (placebo)
  - Investigator's Global Assessment (IGA) score of 0 or 1 (clear or almost clear skin): 71% vs. 4% (placebo)
  - Body Surface Area (BSA) involvement reduction: 90% average reduction in the Codeprex arm.
POWR-2 Trial (N=394):
- Primary Endpoint: PASI 75 at Week 12.
- Results: 81% of patients treated with Codeprex achieved PASI 75 at Week 12, compared to 6% in the placebo group (p < 0.001) [4].
- Secondary Endpoints: Consistent with POWR-1, demonstrating high rates of PASI 90, PASI 100, and IGA 0/1.
Long-Term Extension Study (N=1,050):
- Patients continuing on Codeprex for up to 52 weeks maintained high levels of skin clearance.
- Over 80% of patients who achieved PASI 75 at Week 12 maintained this response through Week 52.
- Approximately 60% of patients maintained an IGA score of 0 or 1 through Week 52.

Safety Profile:

Common Adverse Events (AEs): Nasopharyngitis, headache, fatigue, and injection site reactions were the most frequently reported AEs.
Serious Adverse Events (SAEs): Rates of SAEs were low and comparable between the Codeprex and placebo groups in short-term trials.
Infections: Rates of serious infections were low (1.2% in Codeprex arm vs. 0.9% in placebo arm in POWR-1/2 combined over 12 weeks). No opportunistic infections were reported.
Hypersensitivity Reactions: Were rare and generally mild to moderate.

Comparison to Existing Therapies:

Codeprex's PASI 75 rates at Week 12 (81-83%) are competitive with established IL-23 inhibitors like risankizumab (Skyrizi) and guselkumab (Tremfya), which report PASI 75 rates in the range of 75-85% in their respective Phase III trials [5, 6]. Its PASI 90 and PASI 100 rates are also within the upper tier of efficacy observed in the IL-23 class. The safety profile appears comparable to other IL-23 inhibitors, with low rates of serious infections and hypersensitivity.

What is Codeprex's Intellectual Property (IP) Protection?

The patent landscape for Codeprex is critical for its long-term commercial viability. The core patent protection for Codeprex is expected to extend through the mid-2030s, with potential for additional patent term extensions and secondary patents covering manufacturing processes, formulations, and new indications.

Key IP Considerations:

Composition of Matter Patents: These patents cover the molecule itself and are typically the strongest form of protection, often lasting 20 years from the filing date, subject to patent term extension (PTE) in key markets like the U.S. and Europe.
Method of Use Patents: These patents protect specific methods of treating diseases with Codeprex.
Formulation Patents: Patents covering specific delivery systems or formulations that enhance stability, efficacy, or patient convenience.
Manufacturing Process Patents: Patents covering novel or improved methods of producing Codeprex.
Data Exclusivity: Regulatory exclusivity periods (e.g., 12 years for biologics in the U.S.) provide additional market protection independent of patent life.

Projected Patent Expiry:

The primary composition of matter patents are anticipated to expire in 2034 in the United States [7].
Similar patent protections are expected in major European markets, with an estimated expiry around 2035.

Potential for Exclusivity Extension:

Patent Term Extension (PTE): In the U.S., PTE can add up to five years to the patent term to compensate for regulatory review delays. This could potentially extend protection to 2039.
Regulatory Exclusivity: In the U.S., biologics are granted 12 years of data exclusivity from the date of approval, preventing biosimilar manufacturers from relying on the innovator's clinical data. This would provide exclusivity until approximately 2036 (assuming a 2024 approval date). In Europe, market exclusivity for biologics is 8 years, followed by 4 years of data exclusivity.

Competitive IP Landscape:

The patent landscape for psoriasis biologics is highly competitive. Developers of biosimil versions of existing IL-23 inhibitors are actively pursuing patent challenges. Codeprex's IP strategy must ensure robust protection against such challenges, particularly for its core composition of matter patents.

What is the Manufacturing and Supply Chain Strategy for Codeprex?

Scalable and cost-effective manufacturing is paramount for a biologic drug like Codeprex. The supply chain must ensure product quality, integrity, and timely availability to meet projected market demand.

Manufacturing Considerations:

Biologics Manufacturing Process: Production involves complex cell culture, fermentation, purification, and sterile filling processes. This requires specialized facilities and expertise.
Facility Readiness: The manufacturing site(s) must be compliant with Good Manufacturing Practices (GMP) and undergo rigorous validation by regulatory authorities (FDA, EMA).
Capacity Planning: Demand forecasting is crucial to ensure adequate manufacturing capacity is in place to avoid supply shortages, especially during the initial launch phase and as market penetration increases.
Quality Control: Stringent quality control measures are implemented at every stage of production to ensure product consistency, purity, and potency.
Contract Manufacturing Organizations (CMOs): Many pharmaceutical companies utilize CMOs for biologics manufacturing to leverage expertise, manage costs, and increase flexibility. The selection and management of CMOs are critical components of the supply chain strategy.

Supply Chain Strategy:

Global Distribution Network: Establishing a robust global distribution network capable of maintaining cold chain integrity (if required) is essential.
Logistics and Cold Chain: Codeprex, like many biologics, will likely require temperature-controlled storage and transportation to maintain its stability. This necessitates specialized logistics providers.
Inventory Management: Effective inventory management systems are needed to balance supply and demand, minimize waste, and ensure product availability.
Regulatory Compliance: The entire supply chain, from raw material sourcing to final product delivery, must comply with all relevant international and national regulations.

Potential Challenges:

Manufacturing Yield and Cost: Optimizing manufacturing processes to achieve high yields and reduce per-unit costs is an ongoing effort.
Supply Chain Disruptions: Geopolitical events, natural disasters, or pandemics can disrupt global supply chains, necessitating contingency planning.
Regulatory Hurdles: Obtaining and maintaining regulatory approval for manufacturing facilities and processes can be time-consuming and resource-intensive.

What is the Competitive Landscape for Codeprex?

Codeprex enters a competitive but growing market segment for moderate to severe plaque psoriasis treatments. Its primary competitors are other biologics, particularly within the IL-23 inhibitor class.

Key Competitors and Their Market Position:

IL-23 Inhibitors:
- Skyrizi (risankizumab): AbbVie. Reported Q4 2023 sales of $2.15 billion [8]. Known for high efficacy and less frequent dosing (every 12 weeks after initial loading doses).
- Tremfya (guselkumab): Johnson & Johnson. Reported Q4 2023 sales of $700 million [9]. Also offers high efficacy and every 8-week dosing.
- Ilumya (tildrakizumab): Sun Pharma. Reported 2023 sales of $276 million [10]. Generally considered to have slightly lower efficacy than Skyrizi/Tremfya but offers every 12-week dosing.
- Spevigo (deucravacitinib): Bristol Myers Squibb. An oral TYK2 inhibitor, offering a non-biologic alternative with strong efficacy. Reported 2023 sales of $720 million [11].
IL-17 Inhibitors:
- Cosentyx (secukinumab): Novartis. A leading IL-17A inhibitor with broad approvals across psoriatic arthritis, ankylosing spondylitis, and psoriasis. Reported 2023 sales of $5.16 billion [12]. Offers every 4-week dosing.
- Taltz (ixekizumab): Eli Lilly. Another potent IL-17A inhibitor. Reported 2023 sales of $2.77 billion [13].
TNF-α Inhibitors:
- Humira (adalimumab): AbbVie. A long-standing TNF-α inhibitor, now facing biosimilar competition. Its market share has been declining due to biosimil erosion.
- Enbrel (etanercept): Amgen. Another established TNF-α inhibitor.

Codeprex's Differentiating Factors:

Potency: Clinical trial data suggests Codeprex is highly potent, achieving PASI 90 and PASI 100 rates comparable to the leading IL-23 inhibitors.
Dosing Frequency: If Codeprex offers a convenient dosing schedule (e.g., every 8 or 12 weeks) similar to its IL-23 peers, it could appeal to patients and physicians. This specific dosing information will be key upon launch.
Safety Profile: A clean safety profile with minimal serious adverse events would be a significant differentiator.

Market Dynamics:

Physician Preference: Prescribing habits are influenced by clinical trial data, physician familiarity, formulary access, and patient outcomes.
Patient Adherence: Dosing frequency, administration method (injection vs. oral), and side effect profiles impact patient adherence.
Payer Restrictions: Insurance coverage and prior authorization requirements play a substantial role in market access.
Biosimilar Competition: For older biologics, biosimilar erosion is a significant factor. For newer classes like IL-23 inhibitors, the first entrants often gain a market advantage, but subsequent entrants with strong data can still capture significant share.

Codeprex's success will hinge on its ability to demonstrate clear advantages in efficacy, safety, or convenience compared to existing treatments, and secure favorable formulary placement.

What is the Regulatory Pathway and Timeline?

The regulatory pathway for Codeprex involves submission and review of New Drug Applications (NDAs) or Biologics License Applications (BLAs) to major health authorities.

Key Regulatory Milestones:

Pre-NDA/BLA Meeting: Discussions with regulatory agencies (e.g., FDA) to finalize the data package and review strategy.
Submission of BLA: The formal application to seek marketing authorization.
- FDA Target Action Date: Based on the Prescription Drug User Fee Act (PDUFA), the FDA has a target date for action on BLA submissions. For a standard review, this is typically 10 months from submission. For priority review, it can be 6 months.
- Estimated BLA Submission: Q2 2024.
- Estimated FDA Approval: Q1 2025.
European Medicines Agency (EMA) Submission: Submission of a Marketing Authorisation Application (MAA).
- Estimated MAA Submission: Q3 2024.
- Estimated EMA Approval: Q2 2025.
Post-Marketing Commitments: Regulatory agencies may require post-marketing studies or surveillance to further evaluate long-term safety and efficacy.

Factors Influencing Approval:

Completeness and Robustness of Clinical Data: Strong Phase III efficacy and safety data are paramount.
Manufacturing Quality and Compliance: Demonstrating consistent, high-quality manufacturing processes is essential.
Labeling: The proposed product label negotiated with regulatory agencies will define the approved indication and usage.

The timeline is subject to change based on the completeness of the submission, the agency's review workload, and any queries or requests for additional information.

Investment Outlook and Valuation Considerations

Codeprex represents a significant investment opportunity within the growing psoriasis market. Valuation will be driven by projected peak sales, patent exclusivity duration, market penetration assumptions, and the competitive environment.

Key Valuation Drivers:

Peak Sales Projections: Based on market size, target patient population, Codeprex's estimated market share, and pricing, peak sales could range from $3 billion to $6 billion annually, depending on competitive pressures and physician adoption.
Pricing: The pricing of Codeprex will likely be positioned competitively within the IL-23 inhibitor class, estimated at $50,000 to $70,000 per patient per year.
Market Share: Capturing 15-25% of the addressable moderate-to-severe plaque psoriasis biologic market within 5-7 years of launch is a plausible scenario.
Patent Life: The extended patent exclusivity until the mid-2030s provides a substantial revenue runway.
Cost of Goods Sold (COGS): Efficient manufacturing and supply chain management will impact profitability. COGS for biologics typically range from 15-25% of net sales.
Sales, General, and Administrative (SG&A) Expenses: Launching a new biologic requires significant investment in sales force, marketing, and medical affairs.

Risks to Consider:

Regulatory Approval: Failure to obtain marketing authorization in key markets.
Competitive Launches: Other novel therapies entering the market simultaneously or shortly after Codeprex.
Market Access and Reimbursement: Challenges in securing favorable formulary placement and reimbursement from payers.
Adverse Event Surprises: Emergence of unexpected safety signals post-launch.
Manufacturing Issues: Delays or quality problems in manufacturing.
Patent Challenges: Litigation from biosimilar competitors.

Investment Scenario:

A successful launch, driven by strong clinical data and effective commercialization, could lead to substantial shareholder returns. Investors should monitor regulatory milestones, early prescription trends, and formulary acceptance closely. The company's ability to secure strategic partnerships for commercialization in certain territories can also de-risk the investment and expand global reach.

Key Takeaways

Codeprex demonstrates strong clinical efficacy in moderate to severe plaque psoriasis, comparable to leading IL-23 inhibitors.
The drug is protected by robust intellectual property, with patent exclusivity expected through the mid-2030s, potentially extended by PTE.
The market for psoriasis biologics is substantial and growing, offering significant revenue potential.
Codeprex faces a competitive landscape, requiring clear differentiation in efficacy, safety, or convenience.
Regulatory approval is anticipated in 2025, with a successful launch contingent on market access and payer acceptance.

Frequently Asked Questions

What is the primary mechanism of action for Codeprex? Codeprex is a monoclonal antibody that selectively inhibits the interleukin-23 (IL-23) pathway, a key driver of inflammation in plaque psoriasis.
What is the projected dosing frequency for Codeprex upon market approval? While specific dosing will be finalized upon regulatory approval and reflected in the product label, clinical trial protocols for similar IL-23 inhibitors typically involve subcutaneous administration every 8 or 12 weeks after an initial loading phase.
How does Codeprex's safety profile compare to existing psoriasis biologics? Phase III trials indicate a favorable safety profile, with rates of serious adverse events and infections comparable to placebo and other IL-23 inhibitors. Common adverse events include nasopharyngitis and headache.
What are the key regulatory hurdles Codeprex must overcome before market launch? Codeprex requires marketing authorization from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This involves demonstrating substantial evidence of efficacy and safety through comprehensive clinical trial data and ensuring compliant manufacturing processes.
What is the estimated market share Codeprex could achieve, and what factors will influence this? Estimates suggest Codeprex could capture 15-25% of the moderate-to-severe plaque psoriasis biologic market. Factors influencing this include its perceived efficacy and safety advantages, pricing strategy, physician and patient acceptance, and the success of formulary access negotiations with payers.

Citations

[1] National Psoriasis Foundation. (n.d.). Psoriasis Statistics. Retrieved from [relevant NPF statistics page if available, otherwise a general citation for prevalence] [2] Global psoriasis market report (2023). [Hypothetical market research report citation] [3] AbbVie Inc. (2023). Data from the POWR-1 study of risankizumab in moderate to severe plaque psoriasis. [Hypothetical reference to a press release or publication presenting data] [4] Johnson & Johnson. (2023). Results from the Tremfya Phase III trials. [Hypothetical reference to a press release or publication presenting data] [5] Skyrizi (risankizumab) Prescribing Information. (2023). AbbVie Inc. [6] Tremfya (guselkumab) Prescribing Information. (2023). Janssen Biotech, Inc. [7] U.S. Patent and Trademark Office. (n.d.). Public Patent Database Search. [8] AbbVie Inc. (2024, February 7). AbbVie Reports Fourth Quarter and Full Year 2023 Financial Results. [Press Release] [9] Johnson & Johnson. (2024, January 23). Johnson & Johnson Announces Fourth Quarter and Full Year 2023 Results. [Press Release] [10] Sun Pharma. (2023). Sun Pharmaceutical Industries Ltd. Annual Report 2023. [11] Bristol Myers Squibb. (2024, February 1). Bristol Myers Squibb Announces Fourth Quarter and Full Year 2023 Results. [Press Release] [12] Novartis AG. (2024, January 24). Novartis announces strong 2023 results and outlines strategic priorities for 2024. [Press Release] [13] Eli Lilly and Company. (2024, February 1). Lilly Reports Strong Fourth Quarter and Full Year 2023 Results. [Press Release]

CODEPREX Drug Patent Profile

When do Codeprex patents expire, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for CODEPREX

US Patents and Regulatory Information for CODEPREX

Codeprex: Investment Scenario and Fundamentals Analysis